TGF-β1 CD44V6 bcl-2及p53蛋白在喉鳞状细胞癌组织中的表达及其临床相关性研究

目的：探讨转化生长因子TGF-β1 CD44V6 bcl-2及p53蛋白在喉鳞状细胞癌中的表达与喉鳞状细胞癌患者的病理分级、临床分期和患者生存率间的相互关系，以研究TGF-β1在喉鳞状细胞癌发病机制中的作用。方法：利用免疫组织化学法测定43例喉鳞状细胞癌石蜡切片中TGF-β1、CD44V6、bcl-2及p53蛋白的表达。结果：TGF-β1在病理Ⅰ、Ⅱ、Ⅲ级中阳性表达率分别为86．96％、82．35％和100．00％；CD44V6分别为60．87％、70．59％和100．00％；bcl-2分别为82．61％、94．12％和100．00％；p53分别为26．09％、35．29％和66．67％。结论：①TGF-β1表达与喉鳞状细胞癌的病理分级、临床分期、颈淋巴结转移和患者的3、5年生存率有关，可作为评定喉鳞状细胞癌的进展、预测其转移与预后的指标。②TGF-β1在喉鳞状细胞癌中的表达与CD44V6、bcl-2、p53具有一定的相关性。

The study of the expression, effect and clinical relationship of TGF-β1 CD44V6 bcl-2 and p53 in the larynx squamous carcinoma

OBJECTIVE: This study was to measure the expression of TGF-beta1 in larynx squamous carcinoma, to investigate the relationship between TGF-beta1 and the expressions of CD44V5 , bcl-2 and p53, and the relationship between TGF-beta1 and pathological grading of tumours, the clinical staging and the survival rate of the patients, through which the effect of TGF-beta1 on the pathogenesis of the larynx squamous carcinoma was to be known. METHOD: With immunohistochemistry, the expressions of TGF-beta1, CD44V6, bcl-2 and p53 were measured in the paraffin sections of the larynx squamous carcinoma tissues of 43 patients. RESULT: In pathological grading I, II, III, respectively, the positive expression ratios of TGF-beta1 were 86.96%, 82.35%, 100.00%; CD44V6 were 60.87%, 70.59%, 100.00%; bcl-2 were 82.61%, 94.12%, 100.00%; p53 were 26.09%, 35.29%, 66.67%. CONCLUSION: (1) TGF-beta1 had some relationships to the pathological grading, the clinical staging, the metastasis to cervical lymph node, the survival rates of patients in 3 and 5 years. TGF-beta1 can be used as a marker to evaluate the development and predict the metastasis of tumors and the prognosis of patients. (2) The expression of TGF-beta1 in larynx carcinoma had some correlation to CD44V6, bcl-2 and p53.